,
Horne, R.
Glendinning, E. http://orcid.org/0000-0002-6766-0113
King, K.
Chalder, T.
Sabin, C.
Walker, A. S.
Campbell, L. J.
Mosweu, I.
Anderson, J.
Collins, S.
Jopling, R.
McCrone, P.
Leake Date, H.
Michie, S.
Nelson, M.
Perry, N.
Smith, J. A.
Sseruma, W.
Cooper, V.
Funding for this research was provided by:
Programme Grants for Applied Research (Number RP-PG-0109-10047)
Article History
Received: 12 November 2018
Accepted: 25 April 2019
First Online: 8 July 2019
Ethics approval and consent to participate
: All research procedures have been performed in accordance with the Declaration of Helsinki and the study has been given a favourable ethical opinion for conduct by the National Research Ethics Service (NRES) East of England–Essex Research Ethics Committee (13/EE/0235), 16/09/2013. Good Clinical Practice and in accordance with all applicable regulatory requirements including the Research Governance Framework and the Medicines for Human Use (Clinical Trial) Regulations 2004, 2006 and any subsequent amendments.Written informed consent will be obtained from all participants for both Phase 1 and 2 of the study.
: Not applicable.
: Lucy J Campbell, Simon Collins, Vanessa Cooper, Elizabeth Glendinning, Rebecca Jopling, Kathryn King, Heather Leake Date, Paul McCrone, Mark Nelson, Susan Michie, Iris Mosweu, Jonathan A Smith, Winnie Sseruma, Nicky Perry and Sarah Walker declare that they have no competing interests.Jane Anderson receives grants, personal fees and non-financial support from Gilead Sciences; MSD, Janssen and BMS, and non-financial support from ViiV.Trudie Chalder acknowledges the financial support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.Rob Horne has undertaken speaker engagements with honoraria with the following companies: Abbvie, Amgen, Biogen Idec, Gilead Sciences, GlaxoSmithKline, Janssen, Pfizer, Roche, Shire Pharmaceuticals, MSD, Astellas, Astrazeneca, DRSU, Erasmus and Novartis and TEVA. Professor Rob Horne is founder and shareholder of a UCL-business spin out company (Spoonful of Sugar) providing consultancy on medication-related behaviours to healthcare policy makers, providers and industry.Caroline Sabin has previously received funding for the membership of Data Safety and Monitoring Committees, Advisory Boards, speaker panels and for preparation of educational materials from Gilead Sciences, ViiV Healthcare and Janssen-Cilag.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.